SCHEMBL3226592

SCHEMBL3226592

Cc1c(C(N)=O)cccc1C(=O)N1CCOCC1

nearest known ligand 0.55

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.55
SMN1; SMN2 Q16637 2/20 0.52
GAA P10253 2/20 0.52
NPSR1 Q6W5P4 1/20 0.51
TP53 P04637 1/20 0.51
PKM P14618 1/20 0.51
HTT P42858 2/20 0.50
KMT2A Q03164 4/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
MEN1 O00255 2/20 0.48
TSHR P16473 1/20 0.48
KDM4E B2RXH2 1/20 0.48
HPGD P15428 1/20 0.48
HSD17B10 Q99714 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2377252 0.85 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2GAANPSR1TP53
SCHEMBL12569441 0.84 PKM (0.60) ALDH1A1SMN1; SMN2GAANPSR1TP53
SCHEMBL5349455 0.84 SMN1; SMN2 (0.67) ALDH1A1SMN1; SMN2GAANPSR1TP53
SCHEMBL3227317 0.83 L3MBTL1 (0.55) ALDH1A1TP53HTTKMT2AL3MBTL1
Hydrochloric Acid SCHEMBL17559454 0.83 SMN1; SMN2 (0.65) ALDH1A1SMN1; SMN2GAANPSR1TP53
SCHEMBL15821798 0.82 PKM (0.55) ALDH1A1SMN1; SMN2GAANPSR1TP53
SCHEMBL12547917 0.82 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2GAANPSR1TP53
SCHEMBL2375485 0.82 ALDH1A1 (0.55) ALDH1A1SMN1; SMN2GAANPSR1TP53
SCHEMBL15108841 0.81 USP2 (0.57) ALDH1A1SMN1; SMN2GAANPSR1TP53
SCHEMBL4117812 0.79 TSHR (0.62) ALDH1A1GAANPSR1TP53PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050749-B1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI PHARMACEUTICAL CO LTD (JP) 2017-11-22 EP claimed
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-03-18 US claimed
EP-2050749-A1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-22 EP claimed
EP-2050749-B1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI PHARMACEUTICAL CO LTD (JP) 2017-11-22 EP disclosed
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-03-18 US disclosed
EP-2050749-A1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF PIK3CA, AKT3, AKT1 ALDH1A1 2102/4885SMN1; SMN2 3098/4885GAA 2827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.